SYN X and The Hospital for Sick Kids developing breakthrough therapeutic for diabetes.

(From Chemical Business NewsBase - Press Release)

SYN X Pharma Inc (SYN X) is collaborating with Dr HM Dosch, at The Hospital for Sick children, to bring to market a ground-breaking therapy to prevent the onset of Type 1 diabetes. The collaborative work of SYN X and Dr Dosch has demonstrated its efficacy in a pre-clinical model of Type 1 diabetes. It illustrates that the company's Proteomics Discovery Platform (PDP) can rapidly deliver and validate therapeutic targets to address urgent medical needs and create value for its shareholders. SYN X and Dr Dosch discovered that a very early target of diabetic autoimmunity is not the insulin producing beta-cell, but a fine…